ArticleImmunity, inflammation and disease2025
The Relationship of Platelets With the Clinical Manifestations and Serologic Markers in Systemic Lupus Erythematosus: A Single-Center Retrospective Study.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Value of the Platelet-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Product in the Evaluation of Systemic Lupus Erythematosus Disease Activity.Journal of inflammation research · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThrombocytopenia is a common clinical manifestation of Systemic lupus erythematosus (SLE), and platelets may play a central role in the pathogenesis of immune-mediated inflammatory diseases. The study aimed to investigate the relationship between platelet count and clinical manifestations and serologic markers in systemic lupus erythematosus (SLE).
methodsThis single-center retrospective study extracted demographic data, blood cell counts, complement (C) levels, autoantibody profiles, and clinical presentation information from the electronic medical records of patients with SLE. The SLE Disease Activity Index 2000 (SLEDAI 2000) score was calculated, and Spearman's correlation coefficient was used to evaluate the correlation between platelet count and other variables.
resultsA total of 418 patients with SLE were included in the study. The platelet count was correlated with hemoglobin, complement 3 (C3), and C4 levels; leukocyte, neutrophil, and lymphocyte counts; and the SLEDAI 2000 score. In patients with SLE with thrombocytopenia, the platelet count was associated with the hemoglobin level and a positive direct Coombs' test. The platelet count in patients with SLE without thrombocytopenia was significantly lower compared with the healthy controls, and the platelet count in this group was correlated with C3 and C4 levels, as well as the leukocyte, neutrophil, and lymphocyte counts. The disease characteristics of patients with SLE with thrombocytopenia differed from those of patients with SLE without thrombocytopenia, whereas the clinical features were essentially the same between patients with mild to moderate SLE-associated thrombocytopenia and patients with severe SLE-associated thrombocytopenia.
conclusionPatients with SLE can be categorized into two groups with different clinical features based on the presence or absence of thrombocytopenia. Furthermore, the platelet count correlates with other blood cell counts and complement levels, particularly in patients with SLE without thrombocytopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.